Loading
A phase 3 trial of Rezvilutamide run by Jiangsu HengRui Medicine Co., Ltd. in prostate cancer, now recruiting.
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer is a phase 3 interventional study registered as NCT07241416 by Jiangsu HengRui Medicine Co., Ltd., with 206 participants planned, started 2025-12-05. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer (mHSPC). No results are recorded here; the registry entry is the source.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs).
Shares Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs).
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.